Yi Gao

Yi Gao

Auto-generated profile, based on publicly available information

Yi Gao

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
QLQiang Li
Qiang Li
WZWeituo Zhang
Weituo Zhang
TLTian Liao
Tian Liao
YGYi Gao
Yi Gao
YZYanzhi Zhang
Yanzhi Zhang
BQBiyun Qian
Biyun Qian
Purpose: From 8% to 28% of patients with papillary thyroid carcinoma (PTC) experience recurrence, complicating risk stratification and treatment. We previously identified an inflammatory molecular subtype of PTC associated with poor prognosis. Based on this subtype, we aimed to develop and validate a noninvasive radiomic signature to predict prognosis and treatment response in patients with PTC. Experimental Design: We collected preoperative ultrasound images from two large independent centers (n = 2,506) to develop and validate a deep learning radiomics signature of inflammation (DLRI) for predicting the inflammatory subtype of PTC, including its correlation with prognosis and anti-inflammatory traditional Chinese medicine (TCM) treatment. Training set 1 (n = 64) and internal validation set 2 (n = 1,108) were from Tianjin Medical University Cancer Institute and Hospital. External validation sets 1 (n = 76) and 2 (n = 1,258) were from Fudan University Shanghai Cancer Center. Results: We developed a DLRI to accurately predict PTC’s inflammatory subtype (AUC = 0.97 in training set 1 and AUC = 0.82 in external validation set 1). High-risk DLRI was significantly associated with poor disease-free survival in the first cohort [HR = 16.49, 95% confidence interval (CI), 7.92–34.35, P < 0.001] and second cohort (HR = 5.42, 95% CI, 3.67–8.02, P < 0.001). The DLRI independently predicted disease-free survival, irrespective of clinicopathologic variables (P < 0.001 for all). Furthermore, patients with high-risk DLRI were likely to benefit from anti-inflammatory TCM treatment (HR = 0.19, 95% CI, 0.06–0.55, P = 0.002), whereas those with low-risk DLRI did not. Conclusions: DLRI is a reliable noninvasive tool for evaluating prognosis and guiding anti-inflammatory TCM treatment in patients with PTC. Prospective studies are needed to confirm these findings.

6 January 2025
Verified
Other
Open access
QLQiang Li
Qiang Li
WZWeituo Zhang
Weituo Zhang
TLTian Liao
Tian Liao
YGYi Gao
Yi Gao
YZYanzhi Zhang
Yanzhi Zhang
BQBiyun Qian
Biyun Qian
Clinical characteristics of patients according to the anti-inflammatory TCM treatment in DLRI high risk patients in the internal validation set 2 after propensity score matching.

6 January 2025
Verified
Other
Open access
QLQiang Li
Qiang Li
WZWeituo Zhang
Weituo Zhang
TLTian Liao
Tian Liao
YGYi Gao
Yi Gao
YZYanzhi Zhang
Yanzhi Zhang
BQBiyun Qian
Biyun Qian
Subgroup analysis of the association between DLRI risk groups and disease-free survival in other clinical characteristics in the internal validation set 2.

6 January 2025
Verified
Other
Open access
QLQiang Li
Qiang Li
WZWeituo Zhang
Weituo Zhang
TLTian Liao
Tian Liao
YGYi Gao
Yi Gao
YZYanzhi Zhang
Yanzhi Zhang
BQBiyun Qian
Biyun Qian
Deep learning radiomic feature selection and the establishment of DLRS using the LASSO Cox regression model.

6 January 2025
Verified
Other
Open access
QLQiang Li
Qiang Li
WZWeituo Zhang
Weituo Zhang
TLTian Liao
Tian Liao
YGYi Gao
Yi Gao
YZYanzhi Zhang
Yanzhi Zhang
BQBiyun Qian
Biyun Qian
The specific operational diagrams for the website's predictive classification results.

6 January 2025
Verified
Other
Open access
QLQiang Li
Qiang Li
WZWeituo Zhang
Weituo Zhang
TLTian Liao
Tian Liao
YGYi Gao
Yi Gao
YZYanzhi Zhang
Yanzhi Zhang
BQBiyun Qian
Biyun Qian
Net reclassification index and integrated discrimination improvement statistics in the internal validation set 2.